NCT00200356View on ClinicalTrials.gov

Edaravone-Sodium Ozagrel Comparative Post-Marketing Study on Acute Ischemic Stroke

PHASE4CompletedINTERVENTIONAL
Enrollment

401

Participants

Timeline

Start Date

August 31, 2004

Study Completion Date

October 31, 2006

Conditions
Cerebral Infarction
Interventions
DRUG

Edaravone

Edaravone, at 30 mg, is intravenously administered by drip over 30 minutes b.i.d., in the morning and the evening.

DRUG

Sodium Ozagrel

Sodium Ozagrel, at 80 mg, is intravenously administered by drip over 2 hours b.i.d., in the morning and the evening.

Sponsors
All Listed Sponsors
lead

Mitsubishi Tanabe Pharma Corporation

INDUSTRY